紫杉醇脂质体治疗不同肿瘤分期宫颈癌患者的近期疗效分析

目的：分析紫杉醇酯质体在不同肿瘤分期宫颈癌患者中的治疗效果。方法从该院2014年1月—2016年2月收治的宫颈癌患者中随机抽选51例,根据肿瘤分期将其分为：I期(17)组、IIA期(17)组、IIB期(17)组,行顺铂基础上加用紫杉醇酯质体方案化疗,评定不同分期患者的治疗效果。观察两组治疗前后肿瘤大小变化、不良反应并进行疗效判定。结果 IIB期患者的疾病缓解率为88.2%,明显高于I期、IIA期缓解率的70.6%、76.5%,差异无统计学意义,P<0.05；I期、IIA期、IIB期患者治疗期间均出现不良反应,发生率分别为29.4%、17.6%、11.8%,差异无统计学意义,P>0.05。结论临床宫颈癌患者中实施紫杉醇酯质体化疗效果显著,且随着肿瘤分期升高,化疗效果更为明显,可为随后的手术方案实施提供参考依据。

Short Term Efficacy of Paclitaxel Liposome in the Treatment of Cervical Cancer Patients with Different Tumor Stages

Objective To analyze the effect of paclitaxel liposome in cervical cancer patients with different tumor stages. Methods From cervical cancer patients in our hospital from January 2014 to February 2016 were randomly selected in 51 cases, according to the tumor stage divided:phase I (17) group, group IIA (17), IIb (17) group, cisplatin based on the use of paclitaxel liposome chemotherapy, evaluation of different staging in patients with therapeutic effect. Results Patients with stage IIB disease remission rate was 88.2%, significantly higher than the phase I, IIA remission rate of 70.6%, 76.5%, three groups of statistical difference, (P< 0.05). Phase I, IIA, IIb patients during adverse reactions occurred, incidence rate of 29.4%, 17.6%, 11.8%, respectively. There is no difference in statistics (P> 0.05).Conclusion In patients with cervical can-cer, paclitaxel liposome chemotherapy has a significant effect, and with the increase of tumor stage, chemotherapy effect is more obvious, which can provide reference for the subsequent implementation of the program.